Image

Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India

Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India

Recruiting
18-50 years
Female
Phase N/A

Powered by AI

Overview

This study will be conducted as a prospective cohort study, enrolling all eligible women in their first trimester of pregnancy during a baseline visit during week 6-13 of pregnancy at Government Medical College Hospital, Nagpur. The Hospital provides primary, secondary, and tertiary care and the obstetric department delivers about 10,000 babies a year. The hypothesis is that co-infection of other respiratory viruses (ORV), particularly COVID-19 and Influenza increases the risk of adverse pregnancy outcomes in mothers and babies and could address the current standard of care in India to not vaccinate pregnant women during pregnancy, by either encouraging vaccination against both viruses before planning a pregnancy or during pregnancy based on global data supporting the safety of this strategy.

Description

All pregnant women enrolled in the study will receive standard of care throughout their pregnancy, labor and delivery and post-partum to discharge. Wherever possible, study visits will coincide with regular antenatal (ANC) care and blood draws will be added to standard blood draws during ANC, labor and delivery and postpartum care. Women will be counselled about procedure to reduce the risk of acquiring ORV during pregnancy. Since this study is observational, we do not anticipate any specific safety concerns with study interviews and procedures, but the investigators will monitor potential adverse events to determine if they are likely or possibly study related.

PRIMARY OBJECTIVE: Determine the prevalence, incidence, and maximal severity of symptomatic or asymptomatic COVID-19 in pregnant women to day 42 postpartum/after miscarriage on maternal outcomes. Secondary analysis will evaluate whether influenza/Other Respiratory Viruses (ORV) infection or COVID-19 vaccination modifies or mediates this risk.

SECONDARY OBJECTIVE: Determine the effect of maternal COVID-19 infection on the fetus and/or neonate during pregnancy through day 7 of life. Secondary analysis will focus on whether influenza/ORV or vaccination modifies, and pre-term birth mediates this risk.

EXPLORATORY OBJECTIVE: Characterize patterns and trajectories of host response/ inflammatory biomarkers as potential mediators of COVID-19 ± Influenza and ORV infection on progression to severe illness in pregnant women/mothers admitted to Government Medical College hospital with COVID-19. Modifiers include COVID-19 , Influenza and other ORV vaccinations.

Eligibility

Inclusion Criteria:

        Women aged 18 to 50 years registering for antenatal care (ANC) at Government Medical
        College Hospital (GMC) Nagpur, India
          -  Estimated Gestational Age at registration <14 weeks based on ultrasound report at the
             baseline study visit;
          -  Intends to receive pregnancy, labor and delivery and neonatal care at GMC;
          -  Plans to live within the city limits of Nagpur throughout their pregnancy and labor
             and delivery to facilitate access to GMC for evaluation of ILI and COVID-19 symptoms;
          -  Willing to be contacted two times per week by call or text for ILI/ COVID-19 symptom
             screening and return to GMC for evaluation and an NP swab/evaluation if symptoms are
             reported;
          -  Willing to take temperature with the provided digital thermometer, and maintain a
             symptom diary after training;
          -  Willing to provide information on pregnancy and neonatal outcomes if care occurs
             outside GMC;
          -  Willing to permit venous blood draws on at least 4 timepoints --1) Baseline study
             visit, 2)28-34 weeks, 3) 37 weeks - prior to delivery and 4) after delivery;
          -  Willing to permit blood draws if hospitalized at GMC for COVID-19 infection;
          -  Willing to consent to participate in the study
        Exclusion Criteria:
          -  Anyone who is deemed to have limited decision-making capacity as defined by Boston
             University IRB i.e. Substantial impairment of cognitive functions (e.g. attention,
             comprehension, memory, and intellect), or conditions that might affect their cognitive
             functions.
          -  Anyone who is deemed to have limited capacity to consent as defined by Boston
             University Institutional Review Board (IRB) i.e. The ability to provide legally
             effective consent to enroll in a research study (AAHRPP definition).

Study details
    Influenza
    COVID-19
    SARS-COV-2 Infection
    Other Respiratory Viruses
    Perinatal Morbidity
    Infant Morbidity

NCT06168019

Boston University

26 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.